Results 121 to 130 of about 87,574 (284)

Human inmmunoglobulin in primary immunodeficiencies

Acta Pediátrica de México, 2014
Human immunoglobulin replacement therapy has become a corner- stone in the treatment of patients with primary immunodeficiencies (PID). Currently indicated as first-line therapy for predominantly antibody deficiencies, severe combined immunodeficiencies,
Sheffler Mendoza Selma, Partida Gaytán Armando, Yamazaki Nakashimada Marco Antonio   +2 more
doaj   +1 more source

Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies [PDF]

, 2018
Hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is an autosomal recessive disorder of ectopic calcification due to deficiency of or resistance to intact fibroblast growth factor 23 (iFGF23). Inactivating
Burbelo, Christopher J. Romero, Daniela Egli-Spichtig, Emily Farrow, Farzana Perwad, Ichikawa, Lori C. Guthrie, Mary Scott Roberts, Michael J. Econs, Michael T. Collins, Peter D. Burbelo, Rachel I. Gafni, Shimada, Shoji Ichikawa, Uchida   +14 more
core   +1 more source

Ionic–Bionic Interfaces: Advancing Iontronic Strategies for Bioelectronic Sensing and Therapy

Advanced Science, EarlyView.
Ionic–bionic interfaces for bioelectronics leverage ions as multifunctional mediators that combine mechanical compliance, ionic and electronic functionalities, and therapeutic effects. These systems offer real‐time biosignal transduction, effective wound dressing, responsive drug delivery, and seamless interaction between soft tissues and electronic ...
Yun Goo Ro, Yoojin Chang, Jeeyoon Kim, Seungjae Lee, Sangyun Na, Cheolhong Park, Hyunhyub Ko   +6 more
wiley   +1 more source

Single Center Study Regarding Subucutaneous Immunoglobulins for Secondary Immunodeficiencies in Hematological Malignancies [PDF]

Documenta Haematologica
Purpose: We report a single center study experience with subcutaneous Immunoglobulin administrations in patients with secondary hematological defficiencies, aiming to explore the outcomes of the infectous complications in these patients.
Daniel Nicolae MURARIU, Sinziana BARBU, Loredana CIRLAN, Larisa ZIDARU, Daniel CORIU, Sorina Nicoleta BADELITA   +5 more
doaj   +1 more source

Mutual Exclusion Analysis Shows that DUSP9 Negatively Regulates PD‐L1 Expression and Acts as a Target to Enhance Anti‐PD‐1 Efficacy

Advanced Science, EarlyView.
A mutually exclusive screening system is established to identify negative regulators of highly plastic genes. Dual specificity phosphatase (DUSP9) is a novel negative regulatory molecule of PD‐L1 by dephosphorylating STAT3, and acts as a target molecule in combination with PD‐1 antibody for tumor immunotherapy and a new clinical biomarker for ...
Yuzhe Hu, Ling Tang, Zheng Kuang, Danyi Huang, Ting Li, Gaofei Yin, Yingyu Chen, Wei Guo, Wenling Han, Pingzhang Wang   +9 more
wiley   +1 more source

Irradiated Tumor Cell‐Derived Microparticles Activate Systemic Anti‐Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils

Advanced Science, EarlyView.
Radiotherapy induces tumor cells to release microparticles (RT‐MPs) into the circulation. The mitochondrial DNA carried by these RT‐MPs activates the STING/NLRP3/GSDMD axis in splenic neutrophils, triggering IL‐1β secretion. This, in turn, enhances dendritic cell function and facilitates the formation of cytotoxic T lymphocytes, thereby promoting ...
Yan Hu, Jiacheng Wang, Mengjie Che, Zheng Yang, Jingshu Meng, Xiao Yang, Yue Deng, Zhiyuan Zhou, Yijun Wang, Wenwen Wei, Zhanjie Zhang, Bian Wu, You Qin, Kunyu Yang, Honglin Jin, Fang Huang, Yajie Sun, Lu Wen, Chao Wan   +18 more
wiley   +1 more source

CD20+FCRL4+ B Cells Activate CD8+ T Cells via MHC‐I Restriction in Nasopharyngeal Carcinoma Anti‐Tumor Immunity

Advanced Science, EarlyView.
CD20⁺FCRL4⁺ B cells in nasopharyngeal carcinoma actively cross‐present exogenous tumor antigens via MHC‐I, enhancing CD8⁺ T‐cell activation, memory formation, and cytotoxicity. IFNγ‐driven WDFY4 upregulation facilitates this process. These findings reveal an unconventional B‐cell–mediated antitumor mechanism and indicate potential relevance to ...
Benjian Zhang, Xiaotian Yuan, Kelei Gao, Bo You, Yaxuan Wang, Lai Meng, Zirong Chen, Shaobing Xie, Yunqing Liu, Zijian Dong, Shumin Xie, Ruohao Fan, Fengjun Wang, Junyi Zhang, Zhihai Xie, Yongzhen Mo, Hua Zhang, Weihong Jiang   +17 more
wiley   +1 more source

Osmotic Tension Asymmetry Drives Electrotactic Migration via PDLIM7‐Polarized Microfilament Coordination in Breast Cancer Cells

Advanced Science, EarlyView.
This study establishes an electric field‐induced directional migration model using fluorescence tension probes to visualize microfilament forces and intracellular osmotic pressure dynamics in the electrotactic migration of breast cancer cells. This model delineates how electromechanical interactions among membrane potential, ion channels, OP, traction ...
Ling Zhu, Zihui Zheng, Wang Li, Chenyi Shou, Ying Zhao, Lijun Zhang, Xiaoli Shi, Yunfeng Hu, Huanhuan Zhao, Huiwen Wu, Jun Guo   +10 more
wiley   +1 more source

A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction

Advanced Science, EarlyView.
Obesity involves chronic inflammation and mitochondrial dysfunction. This study identifies cytochrome P450 2E1 (CYP2E1) as a novel inflammatory target in adipose tissue. Its activity increases in obese mice and correlates with inflammation and mitochondrial impairment.
Jinhuan Qiu, Liyuan Gao, Liyang Wang, Xueke Wang, Lin Jia, Mengyan Deng, Liming Tang, Qiang Wen, Na Gao, Haiwei Xu, Hailing Qiao   +10 more
wiley   +1 more source

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source